Pneuma Respiratory Enhances Inhaled Therapies for Better Respiratory Health

Pneuma Respiratory Enhances Inhaled Therapies for Better Respiratory Health Pneuma Respiratory, a leading med-tech and pharmaceutical company, is pioneering innovative solutions in inhaled respiratory therapeutics aimed at transforming respiratory care. With a focus on treating smoking-related lung conditions, Pneuma is…

Read MorePneuma Respiratory Enhances Inhaled Therapies for Better Respiratory Health

Cellistic Unveils Allo Chassis™: Immune-Cloaked iPSC Cell Lines for Cost-Effective Cell Therapy

Cellistic Unveils Allo Chassis™: Immune-Cloaked iPSC Cell Lines for Cost-Effective Cell Therapy Cellistic, a leader in iPSC-based off-the-shelf cell therapy development and manufacturing services, has introduced its innovative Allo Chassis™—a new line of immune-cloaked iPSC cell lines derived from CD34+…

Read MoreCellistic Unveils Allo Chassis™: Immune-Cloaked iPSC Cell Lines for Cost-Effective Cell Therapy

InnoCare Announces Phase III Study Approval of ICP-248 and Orelabrutinib for CLL/SLL in China

InnoCare Announces Phase III Study Approval of ICP-248 and Orelabrutinib for CLL/SLL in China InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focused on developing therapies for cancer and autoimmune diseases, has announced that the Center for Drug…

Read MoreInnoCare Announces Phase III Study Approval of ICP-248 and Orelabrutinib for CLL/SLL in China

BioIntelliSense Teams Up with Hicuity Health for Scalable Continuous Patient Monitoring

BioIntelliSense Teams Up with Hicuity Health for Scalable Continuous Patient Monitoring BioIntelliSense, a leader in continuous health monitoring and clinical intelligence, has announced a strategic partnership with Hicuity Health, a leading provider of tech-enabled virtual care services. This collaboration aims…

Read MoreBioIntelliSense Teams Up with Hicuity Health for Scalable Continuous Patient Monitoring

Innate Pharma’s Lacutamab Receives FDA Breakthrough Therapy Designation for Sézary Syndrome

Innate Pharma’s Lacutamab Receives FDA Breakthrough Therapy Designation for Sézary Syndrome Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to lacutamab, an innovative anti-KIR3DL2…

Read MoreInnate Pharma’s Lacutamab Receives FDA Breakthrough Therapy Designation for Sézary Syndrome

Five-Year Sotyktu (Deucravacitinib) Data Show Consistent Safety and Durable Response in Psoriasis

Five-Year Sotyktu (Deucravacitinib) Data Show Consistent Safety and Durable Response in Psoriasis Bristol Myers Squibb (NYSE:BMY) has announced new five-year data from the POETYK PSO long-term extension (LTE) trial, evaluating Sotyktu (deucravacitinib) in adult patients with moderate-to-severe plaque psoriasis. The…

Read MoreFive-Year Sotyktu (Deucravacitinib) Data Show Consistent Safety and Durable Response in Psoriasis